A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness (Q33839248)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness (English)

1 reference

Europe PubMed Central

29 July 2017

multicenter clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

7

object named as

Alan W Partin

1 reference

Europe PubMed Central

29 July 2017

author name string

Lori J Sokoll

1

1 reference

Europe PubMed Central

29 July 2017

Martin G Sanda

2

1 reference

Europe PubMed Central

29 July 2017

Ziding Feng

3

1 reference

Europe PubMed Central

29 July 2017

Jacob Kagan

4

1 reference

Europe PubMed Central

29 July 2017

Isaac A Mizrahi

5

1 reference

Europe PubMed Central

29 July 2017

Dennis L Broyles

6

1 reference

Europe PubMed Central

29 July 2017

Sudhir Srivastava

8

1 reference

Europe PubMed Central

29 July 2017

Ian M Thompson

9

1 reference

Europe PubMed Central

29 July 2017

John T Wei

10

1 reference

Europe PubMed Central

29 July 2017

Zhen Zhang

11

1 reference

Europe PubMed Central

29 July 2017

Daniel W Chan

12

1 reference

Europe PubMed Central

29 July 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

29 July 2017

Cancer Epidemiology, Biomarkers & Prevention

1 reference

Europe PubMed Central

29 July 2017

19

1 reference

Europe PubMed Central

29 July 2017

5

1 reference

Europe PubMed Central

29 July 2017

1193-1200

1 reference

Europe PubMed Central

29 July 2017

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Biomarkers for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Prostate-specific antigen in the early detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

PSA and new biomarkers within multivariate models to improve early detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

A (-5, -7) proPSA based artificial neural network to detect prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Free prostate-specific antigen in serum is becoming more complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1055-9965.EPI-10-0007

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33839248&oldid=1571711303"